Tag: Cerebral cavernous malformations

In an experimental research using the ROCK inhibitor NRL-1049 to treat cerebral cavernous malformations, Neurelis has started patient dosing.

The Rho kinase (ROCK) inhibitor NRL-1049, a potential treatment for people with cerebral cavernous malformations (CCM), a condition marked by abnormally enlarged capillary cavities in the brain and spinal cord, was dosed in the first two cohorts of the investigational…

Back to top

Registration Form


This will close in 0 seconds

This will close in 0 seconds

WhatsApp Join Telegram